INBRX-100
Mesothelin-targeted IL-2 for solid tumors
PreclinicalIND-enabling
Key Facts
Indication
Mesothelin-targeted IL-2 for solid tumors
Phase
Preclinical
Status
IND-enabling
Company
About Inhibrx Biosciences
Inhibrx leverages its proprietary sdAb platform to create differentiated, multi-specific protein therapeutics designed to overcome the limitations of conventional antibodies. The company's pipeline includes multiple clinical-stage assets targeting oncology and rare diseases, with strategic partnerships in place with major pharmaceutical companies. Inhibrx's approach focuses on optimizing pharmacokinetics, tissue penetration, and manufacturability to develop best-in-class therapies for complex biological targets.
View full company profile